ArticleFrontiers in immunology2025
Pre-treatment cytokines plus TPSA predict biochemical progression-free survival in prostate cancer metastasis and discriminate metastatic status: a retrospective study.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Prostate cancer (PCa) ranks as the second most common malignancy in men worldwide. While serum prostate-specific antigen (PSA) is routinely monitored, its low specificity frequently leads to overdiagnosis. Cytokines within the tumor microenvironment (TME) demonstrate strong tumor-progression associations, but their combined predictive utility with PSA for metastasis and chemotherapy response remains undetermined. This study aimed to quantify cross-sectional differences in pre-treatment cytokine levels based on metastatic status, assess their prognostic value for biochemical progression-free survival in metastatic patients, and characterize cytokine profiles from baseline to biochemical recurrence. Methods: We retrospectively analyzed 328 PCa patients (175 metastatic, 153 non-metastatic), collecting data on age, smoking history, Gleason score, total PSA (TPSA), and cytokines. Metastasis-associated factors were identified by Spearman correlation and logistic regression. Prognostic models were evaluated using ROC curves/AUC analysis. Multi index combination was used to find the best prognostic group.Survival analysis employed Kaplan-Meier methodology, while Cox regression assessed post-chemotherapy PSA rebound predictors. Introduction: We find that smoking, TPSA, and IL-8 emerged as independent metastasis risk factors. Prognostic indices PRE1 (smoking, TPSA, IL-8) and PRE2 (all significant factors) achieved AUCs of 0.788 and 0.787 respectively, with PRE1 demonstrating superior calibration. The AUC of TPSA+IL-6+IL-8+IL-10 four factor combination was 0.753, and this combination yielded high prognostic performance, and the proportion of metastasis group was significantly higher than that of non-metastasis group. Univariate Cox analysis associated age, TPSA, IL-6, IL-8, and TNF-α with PSA rebound, though multivariate analysis identified no independent predictors. Discussion: These results underscore the immunological relevance of specific cytokines in PCa progression and their potential as complementary biomarkers to PSA for improving risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.